Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Perphenazine(click to collapse)
1/4 selected
Perphenazine
Trilafon
First-Generation Antipsychotic
FDA-approved indications
- Schizophrenia
- Severe nausea and vomiting
MechanismPhenothiazine Antipsychotic
Half-life9 to 12 hours
Decision GuideWhen to pick each / when to consider an alternative
Perphenazine
Consider when
- Mid-potency FGA with balanced EPS/sedation profile — intermediate D2 affinity between haloperidol and chlorpromazine
- CATIE trial evidence — only FGA included in landmark CATIE trial; comparable effectiveness to SGAs for chronic schizophrenia
- Cost-effective antipsychotic — generic with decades of use; fraction of brand SGA cost
- Nausea/vomiting — FDA-approved antiemetic indication; useful in patients needing both antipsychotic and antiemetic
- +1 more
Consider an alternative when
- EPS-vulnerable patient — mid-potency still carries meaningful EPS risk; higher than most SGAs
- Tardive dyskinesia concern with long-term use — FGA TD risk higher than SGAs; monitoring essential
- Metabolic monitoring not in place — CATIE showed perphenazine had metabolic effects comparable to some SGAs; not metabolically clean
- Hyperprolactinemia concern — dose-dependent prolactin elevation; less than haloperidol but more than SGAs
- +1 more
| Axis | Perphenazine FGA |
|---|---|
| Boxed Warnings | |
Agranulocytosis / severe neutropenia | |
Cerebrovascular events (elderly w/ dementia) | |
Neuroleptic malignant syndrome (NMS) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Akathisia / EPS | |
Tardive dyskinesia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
| Endocrine | |
Prolactin elevation | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
| Cardiac | |
QTc prolongation | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Dermatologic | |
Photosensitivity / skin pigmentation | |
| Sexual | |
Sexual dysfunction | |
| Interactions | |
CYP interactions / DDI profile | |
| Safety | |
Overdose toxicity | |
| Pregnancy | |
Teratogenicity | |
Lactation / breastfeeding safety | |